Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux

J Infect Dis. 1992 Apr;165(4):723-6. doi: 10.1093/infdis/165.4.723.

Abstract

To assess the response to and tolerance of recombinant interferon-alpha administration in patients with chronic hepatitis C and human immunodeficiency virus (HIV) infection, 12 patients with chronic hepatitis C and HIV infection were given interferon-alpha, 1, 3, or 5 million units thrice weekly, for 4 or 6 months. Four patients had a complete response (normal serum alanine aminotransferase activity [ALT]), 3 had a near-complete response (serum ALT less than one-and-one-half times the upper limit of normal), and 5 had no response at the end of administration. Histologic examination of liver showed an improvement in 1 patient with complete response and no improvement in another patient with no response. In patients with chronic hepatitis C with HIV infection, the response to and tolerance of recombinant interferon-alpha were not different from those usually observed in patients with chronic hepatitis C infection without HIV infection.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • CD4-Positive T-Lymphocytes
  • Chronic Disease
  • Female
  • Follow-Up Studies
  • HIV Infections / complications*
  • Hepatitis C / complications
  • Hepatitis C / therapy*
  • Humans
  • Interferon Type I / therapeutic use*
  • Leukocyte Count
  • Liver Cirrhosis / complications
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Treatment Outcome

Substances

  • Interferon Type I
  • Recombinant Proteins